Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
N-Benzyllinolenamide
Cat. No.:
0225LY-0531
Appearance:
Liquid
Purity:
≥99%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
N-Benzyllinolenamide is a natural inhibitor of fatty acid amide hydrolase (FAAH), with an IC50 of 41.8 μM.
Synonym:
N-Benzyllinolenamide; 883715-18-2; N-Benzyl-(9z,12z,15z)-octadecatrienamide; (9Z,12Z,15Z)-N-Benzyloctadeca-9,12,15-trienamide
CAS No.:
883715-18-2
Compound CID:
68741582
Formula:
C25H37NO
Formula Weight:
367.57
Specification
Targets&IC50:
FAAH: 41.8 μM
Relative Density:
0.943±0.06 g/cm3 at 20°C, 760 mmHg.
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
N-Benzyllinolenamide can be used in neuroprotection research to study its role in mitigating neuroinflammation and promoting neuronal survival.
Library Information
Target:
FAAH
Receptor:
FAAH
Pathways:
Neuronal signaling; Autophagy; Metabolism
Plate Number:
AOCL-7
Plate Location:
h5
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
25 mg/mL; 68.01 mM
